^
CANCER:

Biliary Tract Cancer

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
FGFR2 rearrangement
Cholangiocarcinoma
pemigatinib
Sensitive
:
A1
PRNewswire - 1 week - (New A1)
FGFR2 fusion
Cholangiocarcinoma
pemigatinib
Sensitive
:
A1
PRNewswire - 1 week - (New A1)
No biomarker
Biliary Tract Cancer
durvalumab
Sensitive
:
A1
FDA - 3 weeks - (New A1)
FGFR2 fusion
Cholangiocarcinoma
ARQ 087
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
FGFR2 amplification
Cholangiocarcinoma
ARQ 087
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
IDH1 R132C + PIK3CA E545K + IDH2 R172K
Cholangiocarcinoma
ivosidenib
Resistant
:
C4
NPJ Precis Oncol - 3 weeks - (New C4)
FGFR2 M540_I541insMM
Cholangiocarcinoma
pemigatinib
Sensitive
:
C4
Target Oncol - 3 weeks - (New C4)
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive
:
A1
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive
:
A1
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive
:
A1
MSI-H/dMMR
Biliary Tract Cancer
pembrolizumab
Sensitive
:
A1
No biomarker
Gallbladder Cancer
GC
Sensitive
:
A2
No biomarker
Gallbladder Cancer
GemOx
Sensitive
:
A2
No biomarker
Gallbladder Cancer
gemcitabine
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
CAPOX
Sensitive
:
A2
No biomarker
Gallbladder Cancer
GEM-CAP
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
FP
Sensitive
:
A2
No biomarker
Gallbladder Cancer
CAPOX
Sensitive
:
A2
No biomarker
Gallbladder Cancer
XP
Sensitive
:
A2
No biomarker
Gallbladder Cancer
FP
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
XP
Sensitive
:
A2
No biomarker
Cholangiocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Gallbladder Cancer
capecitabine
Sensitive
:
A2
No biomarker
Gallbladder Cancer
5-fluorouracil
Sensitive
:
A2
No biomarker
Gallbladder Cancer
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Gallbladder Cancer
5-fluorouracil + oxaliplatin
Sensitive
:
A2
No biomarker
Cholangiocarcinoma
gemcitabine
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
gemcitabine
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
capecitabine
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
5-fluorouracil
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
BRAF V600E
Biliary Tract Cancer
trametinib + dabrafenib
Sensitive
:
A2
NTRK3 fusion
Biliary Tract Cancer
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Biliary Tract Cancer
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Biliary Tract Cancer
entrectinib
Sensitive
:
A2
NTRK2 fusion
Biliary Tract Cancer
entrectinib
Sensitive
:
A2
NTRK1 fusion
Biliary Tract Cancer
entrectinib
Sensitive
:
A2
NTRK1 fusion
Biliary Tract Cancer
larotrectinib
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
gemcitabine + oxaliplatin
Sensitive
:
A2